# Flexible Bronchoscopy and Interventional Pulmonology

## Flexible Bronchoscopy

### Indications

Flexible bronchoscopy serves both diagnostic and therapeutic purposes across a broad range of clinical scenarios. Diagnostic indications include evaluation of unexplained hemoptysis to localize the bleeding source and identify endobronchial lesions; investigation of suspected lung cancer through endobronchial biopsy, brushing, bronchoalveolar lavage, transbronchial needle aspiration, and EBUS-guided transbronchial needle aspiration; evaluation of pulmonary infiltrates, particularly in immunocompromised patients, where BAL provides material for comprehensive infectious workup, and in patients with suspected ILD, sarcoidosis, or organizing pneumonia, where transbronchial lung biopsy yields diagnostic tissue; assessment of mediastinal and hilar lymphadenopathy via EBUS-TBNA for staging and diagnosis; investigation of suspected foreign body aspiration; evaluation of persistent unexplained cough, stridor, or wheeze not explained by other testing; upper airway assessment for vocal cord dysfunction, tracheal stenosis, and tracheomalacia; and surveillance transbronchial biopsy for rejection monitoring in lung transplant recipients.

Therapeutic indications for flexible bronchoscopy encompass mucus plug removal and therapeutic aspiration of retained secretions, foreign body retrieval using grasping forceps or retrieval baskets, management of hemoptysis through cold saline lavage, topical epinephrine application, and balloon tamponade, airway stent placement (both silicone and metallic), bronchoscopic lung volume reduction with endobronchial valves, whole-lung lavage for pulmonary alveolar proteinosis, and endobronchial ablation using electrocautery, argon plasma coagulation, laser, or cryotherapy.

### Technique and Safety

Flexible bronchoscopy is performed under moderate sedation using midazolam combined with fentanyl or propofol, or under general anesthesia when more complex interventions are anticipated. Topical lidocaine is applied to the airways to suppress cough and minimize discomfort, with the maximum recommended dose being 7 mg/kg for topical administration, which translates to a maximum of approximately 28 mL of 1% lidocaine in a 70 kg patient. Exceeding this dose risks lidocaine toxicity, manifesting as seizures and cardiac arrhythmias.

The complication profile of flexible bronchoscopy is generally favorable. Hypoxemia is the most common complication, resulting from airway suctioning, sedation-induced hypoventilation, and the bronchoscope itself partially obstructing the airway. Bleeding following biopsy is usually self-limited and manageable with topical measures. Pneumothorax occurs in 1% to 4% of transbronchial biopsies, necessitating post-procedure vigilance and a low threshold for chest radiography. Post-procedure fever develops in 10% to 15% of patients, particularly following BAL, and is typically transient and self-resolving. Laryngospasm and bronchospasm are rare but potentially serious complications. Contraindications to bronchoscopy include refractory hypoxemia that cannot be adequately supported during the procedure, severe coagulopathy (INR greater than 1.5 or platelets below 50,000 for biopsy procedures, though inspection and BAL may be performed at lower thresholds), unstable cardiac arrhythmias, and the absence of informed consent.

### BAL (Bronchoalveolar Lavage)

Bronchoalveolar lavage is a fundamental bronchoscopic technique that samples the cellular and acellular components of the alveolar space. The technique involves wedging the bronchoscope into a segmental bronchus, typically the right middle lobe or lingula for ILD evaluation due to their favorable anatomy, instilling 100 to 300 mL of sterile normal saline in sequential 20 to 60 mL aliquots, and recovering the fluid by gentle suction, with a typical return of 40% to 60% of the instilled volume. Cell count and differential analysis of the recovered fluid reveals the alveolar cellular milieu: normal values include 80% to 90% macrophages, 5% to 15% lymphocytes, less than 3% neutrophils, and less than 1% eosinophils. Abnormal patterns provide diagnostic clues as detailed in the ILD classification lecture. Microbiologic studies performed on BAL fluid include bacterial, fungal, and mycobacterial cultures; Pneumocystis staining (methenamine silver or direct fluorescent antibody); respiratory viral PCR panel; and galactomannan assay for Aspergillus.

### Transbronchial Biopsy (TBBx)

Transbronchial biopsy involves advancing biopsy forceps through the bronchoscope working channel to the lung periphery, typically under fluoroscopic guidance to confirm appropriate positioning and minimize pneumothorax risk. Five to ten biopsy specimens are generally obtained to maximize diagnostic yield. The diagnostic yield varies by disease: sarcoidosis is diagnosed in 60% to 70% of cases (given its peribronchovascular distribution), organizing pneumonia in approximately 60%, lymphangitic carcinomatosis in approximately 60%, and other forms of ILD with variable yield of 30% to 60%. Complications include pneumothorax in 1% to 4% and significant bleeding in 1% to 2% of procedures. The principal limitation of transbronchial biopsy is the small tissue sample size, which may be insufficient for the architectural assessment required to diagnose many forms of ILD; in these cases, transbronchial cryobiopsy or surgical lung biopsy provides larger, better-preserved specimens.

<image>A detailed bronchial anatomy diagram showing the tracheobronchial tree from the operator's perspective during bronchoscopy. Display both right and left bronchial systems with labeled segments. Right side: RUL (apical B1, posterior B2, anterior B3), bronchus intermedius, RML (lateral B4, medial B5), RLL (superior B6, medial basal B7, anterior basal B8, lateral basal B9, posterior basal B10). Left side: LUL (apical-posterior B1+2, anterior B3, superior lingula B4, inferior lingula B5), LLL (superior B6, anteromedial basal B7+8, lateral basal B9, posterior basal B10). Include actual bronchoscopic view insets at key landmarks: main carina (showing sharp, thin, mobile carina), right upper lobe takeoff, and left upper lobe takeoff. Label the subcarinal space accessible by EBUS-TBNA.</image>

## EBUS (Endobronchial Ultrasound)

### Convex Probe EBUS (CP-EBUS)

Convex probe endobronchial ultrasound has revolutionized the evaluation of mediastinal and hilar pathology by enabling real-time ultrasound-guided transbronchial needle aspiration. The convex probe EBUS bronchoscope incorporates a curvilinear ultrasound transducer at its tip, providing a sector image that allows visualization of structures adjacent to the airway wall while simultaneously guiding a needle passed through the bronchoscope working channel into the target lesion. Accessible lymph node stations include 2R, 2L, 4R, 4L, 7 (subcarinal), 10R, 10L, 11R, 11L, 12R, and 12L, providing comprehensive coverage of the paratracheal, subcarinal, and hilar regions.

EBUS-TBNA has replaced mediastinoscopy as the first-line modality for mediastinal staging of lung cancer, a transition validated by the ASTER trial, which demonstrated that EBUS combined with endoscopic ultrasound (EUS) was superior to mediastinoscopy alone for mediastinal staging. The diagnostic yield exceeds 90% for mediastinal lymph nodes, with a sensitivity of 89% and specificity approaching 100%. The combination of EBUS with EUS (or EUS-B, using the EBUS scope transesophageally) further improves sensitivity by accessing lymph node stations not reachable by EBUS alone, including the left adrenal gland, paraesophageal nodes, and aortopulmonary window nodes. Rapid on-site evaluation (ROSE) by a cytopathologist provides immediate assessment of specimen adequacy during the procedure, reducing the number of needle passes needed and improving overall diagnostic yield.

### Radial Probe EBUS (RP-EBUS)

Radial probe endobronchial ultrasound utilizes a miniature ultrasound probe, typically 20 MHz, inserted through the working channel of a standard bronchoscope. The probe generates a 360-degree cross-sectional ultrasound image of the structures surrounding the probe tip, allowing identification and localization of peripheral pulmonary lesions that are beyond direct bronchoscopic visualization. The relationship between the ultrasound probe and the target lesion is categorized as either "concentric" (the probe appears within the lesion) or "eccentric" (the probe is adjacent to the lesion); a concentric view is associated with a significantly higher diagnostic yield than an eccentric view. Radial EBUS is typically combined with a guide sheath technique, in which a catheter sheath is advanced alongside the probe to the target lesion, the probe is then withdrawn, and biopsy instruments are passed through the sheath to sample the identified lesion.

### EBUS Elastography

Strain elastography during EBUS-TBNA is an emerging technique that assesses the stiffness characteristics of lymph nodes by measuring tissue deformation in response to probe compression. Malignant lymph nodes tend to be stiff and homogeneous in their elastographic pattern, while benign reactive nodes tend to be softer and more heterogeneous. This technique may reduce unnecessary biopsies of benign-appearing nodes, though it remains an evolving tool that has not yet been incorporated into standard clinical algorithms.

## Transbronchial Lung Cryobiopsy (TBLC)

### Technique

Transbronchial lung cryobiopsy has emerged as an important innovation that bridges the diagnostic gap between conventional forceps transbronchial biopsy and surgical lung biopsy. A flexible cryoprobe of 1.9 mm or 2.4 mm diameter is inserted through the bronchoscope and advanced to the lung periphery under fluoroscopic guidance. The probe tip is activated for 3 to 5 seconds, rapidly cooling to approximately -75 degrees Celsius and freezing the surrounding tissue onto the probe. The probe and bronchoscope are then rapidly extracted together as a unit, yielding the frozen tissue specimen. This technique produces substantially larger tissue samples (5 to 10 mm) compared with conventional forceps biopsy (1 to 3 mm), with superior preservation of tissue architecture because the freezing mechanism avoids the crush artifact inherent to forceps biopsy. Typically 3 to 5 biopsies are obtained from 2 different sites (different lobes or segments) to maximize diagnostic yield and capture disease heterogeneity.

### Evidence

The COLDICE trial, a landmark prospective comparative study, demonstrated that transbronchial lung cryobiopsy achieved diagnostic agreement with surgical lung biopsy of 70.8% at the level of multidisciplinary conference confidence, suggesting that TBLC may obviate the need for surgical lung biopsy in the majority of ILD cases. The overall diagnostic yield for ILD ranges from 70% to 80% across published series. The complication profile is intermediate between conventional TBBx and surgical lung biopsy: pneumothorax occurs in approximately 10% of cases, and significant bleeding occurs in 5% to 10% of cases. Prophylactic placement of a Fogarty balloon blocker in the segmental bronchus proximal to the biopsy site is widely practiced to control bleeding by inflating the balloon to achieve tamponade if necessary. TBLC is increasingly adopted as an intermediate diagnostic step between conventional TBBx and surgical lung biopsy in the ILD diagnostic pathway, particularly for patients who may not be surgical candidates or who wish to avoid the morbidity of a surgical procedure.

## Interventional Pulmonology Procedures

### Rigid Bronchoscopy

Rigid bronchoscopy, performed under general anesthesia, maintains a central role in interventional pulmonology despite the versatility of flexible bronchoscopy. The rigid bronchoscope is a hollow metallic tube that provides a large working channel accommodating stents, suction catheters, biopsy forceps, and ablation instruments while simultaneously allowing ventilation through the scope itself. Its primary indications include management of central airway obstruction (both malignant and benign), massive hemoptysis requiring airway control and tamponade, retrieval of large foreign bodies, placement of silicone airway stents, and tracheal dilation for stenosis. Any center performing complex airway procedures should have rigid bronchoscopy capability available on a 24/7 basis to manage emergent airway complications.

### Endobronchial Ablation Techniques

| Technique | Mechanism | Contact | Onset of Effect | FiO2 Restriction | Best For |
|-----------|-----------|---------|----------------|-------------------|----------|
| Electrocautery | Thermal energy via direct contact | Contact | Immediate | No | Rapid tumor debulking; hemostasis; snare excision of pedunculated lesions |
| Argon plasma coagulation (APC) | Ionized argon gas plasma arc | Non-contact | Immediate | No | Superficial coagulation; hemostasis; avoids deep tissue injury |
| Nd:YAG laser | High-power thermal ablation | Non-contact | Immediate | FiO2 < 0.40 (airway fire risk) | Bulky endoluminal tumors; deeper penetration |
| Cryotherapy | Freeze-thaw cycles; ice crystal formation | Contact | Delayed (days) | No | Carcinoid tumors; granulation tissue; spray cryo for mucosal lesions |
| Photodynamic therapy (PDT) | Photosensitizer + laser activation -> ROS | Non-contact | Delayed (48-72 h) | No | Superficial endobronchial carcinoma; 4-6 week photosensitivity |

Several endobronchial ablation modalities are available for the management of endobronchial tumors, benign lesions, and hemostasis. Electrocautery delivers thermal energy through direct tissue contact for tumor debulking and hemostasis; a snare attachment enables excision of pedunculated lesions. Electrocautery is rapid, widely available, and relatively inexpensive. Argon plasma coagulation (APC) is a non-contact technique in which argon gas is ionized by a high-frequency current, creating a plasma arc that coagulates tissue surfaces without direct instrument contact; it is particularly suited for superficial tumor coagulation and hemostasis while avoiding deep tissue injury. Nd:YAG laser provides high-power ablation for bulky endoluminal tumors with deeper tissue penetration than other modalities; its use requires reducing the FiO2 to below 0.40 during treatment to prevent airway fire, a potentially catastrophic complication. Cryotherapy employs freeze-thaw cycles to destroy tissue through ice crystal formation and microvascular thrombosis; its effect is delayed, with tumor necrosis developing over days rather than immediately. Spray cryotherapy is effective for mucosal lesions, and cryotherapy is well suited for carcinoid tumors and granulation tissue. Photodynamic therapy (PDT) involves systemic administration of a photosensitizer (porfimer sodium) followed by laser activation within the airway, generating reactive oxygen species that destroy the sensitized tissue; it is indicated for superficial endobronchial carcinoma but produces prolonged photosensitivity lasting 4 to 6 weeks post-treatment, requiring patients to avoid direct sunlight.

### Airway Stents

| Stent Type | Placement Method | Removability | Tumor Ingrowth Risk | Migration Risk | Key Advantage | Key Limitation |
|-----------|-----------------|-------------|---------------------|---------------|---------------|----------------|
| Silicone (Dumon) | Rigid bronchoscopy only | Fully removable | None (solid wall) | Higher | Removable; no ingrowth; preferred for benign disease | Requires rigid bronchoscopy; migration risk |
| Uncovered SEMS | Flexible bronchoscopy | Extremely difficult/impossible once epithelialized | High (mesh interstices) | Lower | Easy placement; conforms to anatomy | Avoid in benign disease; granulation tissue; fracture risk |
| Covered SEMS | Flexible bronchoscopy | Removable (easier than uncovered) | Reduced (membrane coating) | Intermediate | Flexible placement + reduced ingrowth | Membrane may degrade; still risk of granulation at margins |

Airway stents provide structural support for airways compromised by intrinsic or extrinsic obstruction. Silicone stents (Dumon type) are placed exclusively via rigid bronchoscopy, are fully removable, and resist tumor ingrowth due to their solid wall construction; disadvantages include a tendency to migrate and the need for rigid bronchoscopy for any repositioning. Self-expanding metallic stents (SEMS) can be placed via flexible bronchoscopy, conform to irregular airway anatomy, and are available in uncovered and covered varieties. Uncovered metallic stents carry a significant risk of tumor ingrowth through the mesh interstices and become extremely difficult or impossible to remove once epithelialized; covered SEMS partially address the ingrowth issue through their membrane coating.

Stent indications include malignant central airway obstruction (the most common indication), benign tracheal stenosis (post-intubation or post-tracheostomy), tracheobronchomalacia, external compression, and tracheoesophageal fistula. A critical practice point is that permanent metallic stents should not be placed for benign airway disease due to the risks of granulation tissue formation at the stent margins, stent fracture, erosion into adjacent structures, and the inability to remove the stent if complications develop. For benign indications, silicone stents or covered removable metallic stents are strongly preferred.

### Endobronchial Valves (EBV) for Lung Volume Reduction

Endobronchial valve placement represents a bronchoscopic alternative to lung volume reduction surgery for selected patients with severe emphysema. One-way Zephyr valves are placed in the segmental bronchi of a targeted lobe, allowing air and secretions to exit during expiration while blocking inspiratory airflow, thereby achieving lobar atelectasis that is physiologically equivalent to surgical resection of the hyperinflated lobe.

Patient selection is rigorous and critical to procedural success. Eligibility criteria include heterogeneous emphysema distribution, significant hyperinflation with residual volume exceeding 175% of predicted, FEV1 between 15% and 45% of predicted, intact interlobar fissure with no collateral ventilation, and a 6-minute walk distance exceeding 100 meters. Collateral ventilation assessment is performed using the Chartis catheter, a balloon-tipped catheter placed in the target lobe bronchus that measures airflow from collateral pathways; a negative Chartis result (no collateral ventilation) predicts procedural success, while a positive result (significant collateral flow) indicates that lobar atelectasis will not be achieved and the procedure should not be performed.

The LIBERATE trial demonstrated that Zephyr endobronchial valves improved FEV1 by 18%, increased 6-minute walk distance, and reduced dyspnea compared with medical therapy alone. The most important and frequent complication is pneumothorax, occurring in 25% to 30% of patients. This high rate results from the rapid development of lobar atelectasis creating asymmetric forces within the thorax; when the target lobe collapses, the adjacent lobe may overexpand and rupture, producing a pneumothorax that requires chest tube drainage. Because of this risk, all patients undergoing endobronchial valve placement should be monitored in the hospital for 3 to 5 days following the procedure.

<image>A multi-panel interventional pulmonology toolkit illustration. Panel 1: Endobronchial ablation - show electrocautery probe delivering thermal energy to an endobronchial tumor causing tissue coagulation; show APC probe with argon gas ionization creating non-contact coagulation; show cryoprobe with ice ball formation at tissue contact. Panel 2: Airway stent placement - show three stent types side by side: Dumon silicone stent (cylindrical, studs on outer surface, placed via rigid bronchoscope), uncovered SEMS (mesh design, self-expanding), covered SEMS (membrane-covered mesh). Show before/after of a tracheal stent opening a compressed airway. Panel 3: Endobronchial valves - show Zephyr valve design (one-way valve allowing air and secretion out, blocking air in), placement in a segmental bronchus via flexible bronchoscopy, and the resulting lobar atelectasis on CXR. Panel 4: Cryobiopsy - show cryoprobe tip with frozen tissue specimen attached, being withdrawn through the bronchoscope. Label each technique with its primary indication.</image>

### Robotic and Navigation Bronchoscopy

Electromagnetic navigation bronchoscopy (ENB) uses an electromagnetic field generator and a CT-reconstructed virtual airway map to guide biopsy tools to peripheral pulmonary lesions beyond the reach of conventional bronchoscopy. The NAVIGATE multicenter study reported a diagnostic yield of 73% with a pneumothorax rate of 4.3%. Limitations include CT-to-body divergence (discrepancy between the virtual map and the patient's actual anatomy due to respiratory motion, atelectasis, or patient movement), which can reduce navigational accuracy and diagnostic yield.

Robotic bronchoscopy represents the latest evolution in bronchoscopic technology, with several commercially available platforms including the Ion system (Intuitive Surgical), Monarch system (Johnson & Johnson/Auris Health), and Galaxy system (Noah Medical). These systems employ telescoping catheter designs that provide superior peripheral reach with stability that exceeds what is achievable with conventional flexible bronchoscopy, enabling access to smaller and more peripherally located pulmonary nodules. Early clinical studies report diagnostic yields of 80% to 90%, which are higher than those achieved with electromagnetic navigation bronchoscopy, with lower pneumothorax rates. These platforms incorporate advanced navigation technologies including vision-based navigation, shape-sensing technology, and integration with radial EBUS and on-site cone-beam CT (CBCT) for real-time confirmation of tool-in-lesion positioning. The field is rapidly evolving, with ongoing trials comparing robotic approaches with conventional techniques and defining optimal patient selection criteria.

### Whole Lung Lavage (WLL)

Whole lung lavage is the gold standard treatment for symptomatic pulmonary alveolar proteinosis (PAP), a condition characterized by accumulation of surfactant-derived lipoproteinaceous material in the alveolar spaces. The procedure is performed under general anesthesia using a double-lumen endotracheal tube that allows independent ventilation and lavage of each lung. One lung is ventilated while the contralateral lung is sequentially filled with warmed normal saline (typically 10 to 15 liters per lung) and drained by gravity. The lavage is repeated until the effluent fluid clears, indicating adequate removal of the accumulated proteinaceous material. The procedure is performed on one lung at a time, with the second lung typically lavaged 1 to 2 weeks later. The therapeutic effect may last months to years, though some patients require repeated lavage procedures for recurrent symptoms.

## Key Clinical Pearls

- EBUS-TBNA has replaced mediastinoscopy as the first-line modality for mediastinal staging of lung cancer; combined EBUS + EUS provides the most comprehensive minimally invasive mediastinal assessment
- Transbronchial lung cryobiopsy is increasingly used as an intermediate diagnostic step between TBBx and surgical lung biopsy for ILD; COLDICE trial showed 70.8% diagnostic agreement with SLB
- Permanent uncovered metallic stents should NOT be placed for benign airway disease due to risks of granulation tissue, fracture, and inability to remove; silicone or covered removable stents are preferred
- Endobronchial valve placement requires confirmed fissure integrity (intact interlobar fissure + negative Chartis collateral ventilation assessment); without this, lobar atelectasis will not occur and the procedure will fail
- Pneumothorax occurs in 25-30% of patients after endobronchial valve placement and typically presents within the first 72 hours; all patients should be monitored in-hospital for 3-5 days post-procedure

## References
1. Du Rand IA, Blaikley J, Booton R, et al. British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults. Thorax. 2013;68(Suppl 1):i1-i44.
2. Criner GJ, Sue R, Wright S, et al. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE). Am J Respir Crit Care Med. 2018;198(9):1151-1164.
3. Troy LK, Grainge C, Corte TJ, et al. Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. Lancet Respir Med. 2020;8(2):171-181.
4. Wahidi MM, Herth F, Yasufuku K, et al. Technical Aspects of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: CHEST Guideline and Expert Panel Report. Chest. 2016;149(3):816-835.
5. Fielding DIK, Bashirzadeh F, Son JH, et al. First Human Use of a New Robotic-Assisted Fiber Optic Sensing Navigation System for Small Peripheral Pulmonary Nodules. Respiration. 2019;98(2):142-150.